Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
Authors Zhou S, Feng Q, Zhang J, Zhou H, Jiang Z, Liang J, Pei W, Liu Q, Zhou Z, Wang X
Received 22 November 2020
Accepted for publication 9 March 2021
Published 30 March 2021 Volume 2021:16 Pages 559—568
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Zhi-Ying Wu
Sicheng Zhou,1,* Qiang Feng,1,* Jing Zhang,2 Haitao Zhou,1 Zheng Jiang,1 Jianwei Liang,1 Wei Pei,1 Qian Liu,1 Zhixiang Zhou,1 Xishan Wang1
1Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Department of Abdominal Surgery, Huanxing Cancer Hospital, Beijing, 100122, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianwei Liang; Wei Pei Email [email protected]; [email protected]
Purpose: Cytoreductive surgery (CRS) added with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the survival rate of certain patients with peritoneal metastasis (PM). However, the perioperative safety and long-term survival of this intricate and possibly life-threatening procedure in elderly patients (≥ 65 years) remain controversial.
Methods: Patients with PM due to appendiceal or colorectal tumours who underwent CRS/HIPEC were evaluated systematically at the National Cancer Center of China and the Huanxing Cancer Hospital between June 2017 and June 2019. The recruited subjects were retrospectively categorized into elderly (age ≥ 65) and non-elderly (age< 65) groups according to their age. Clinical and pathological features, postoperative outcomes, and prognoses were gathered and analysed.
Results: Both groups had similar overall morbidity (56.0% vs 38.7%, P=0.130) and grade 3/4 morbidity (28.0% vs 20.0%, P=0.403) after CRS/HIPEC. However, more patients in the elderly group suffered from ileus postoperatively (16.0% vs 2.6%, P=0.033). After a follow-up period of a median of 20 months, it was concluded that elderly patients had significantly worse 3-year overall survival (OS) than non-elderly patients (16.3% vs 51.4%, P=0.001). Independent prognostic factors were identified to be a high peritoneal carcinomatosis index (PCI) score (HR, 1.10, 95% CI, 1.04– 1.16; P=0.001) and age ≥ 65 (HR, 2.42, 95% CI, 1.32– 4.45; P=0.004) were independent prognostic factors through cox regression analysis.
Conclusion: CRS and HIPEC are related with an elevated prevalence of postoperative ileus but not with the overall morbidity or the grade 3/4 morbidity in elderly patients. However, since worse survival outcomes were observed more commonly in elderly patients compared to younger patients from CRS+HIPEC, this complex and potentially life-threatening procedure should be considered carefully in patients aged ≥ 65 years.
Keywords: elderly patients, CRS, HIPEC, morbidity, survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]